United States

Palatin Technologies Inc (PTN.A)

PTN.A on American Stock Exchange

22 Sep 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Palatin Technologies reports Q4 loss $0.09/shr
Tuesday, 20 Sep 2016 07:30am EDT 

Palatin Technologies Inc : Palatin Technologies, Inc. reports fourth quarter and fiscal year 2016 results . Q4 loss per share $0.09 .There were no revenues recorded in quarter or year ended June 30, 2016 or in quarter ended June 30, 2015.  Full Article

Palatin Technologies entered commercial supply agreement with unit of Catalent Pharma solutions
Thursday, 23 Jun 2016 10:22am EDT 

Palatin Technologies: On june 20, 2016 co entered commercial supply agreement with unit of catalent pharma solutions with an effective date of june 10 . Sec filing . Palatin intends to engage third parties to provide catalent with a supply of bremelanotide and disposable auto-injector device . All patients are projected to complete phase 3 clinical trials of bremelanotide for hypoactive sexual desire disorder, by q3 2016 . Palatin Technologies Inc Says Catalent Will Have Right To Supply At Least 80% Of Palatin's Needs For Product During Term Of Agreement . Initial term of agreement will continue for period of 5 years after date that is 60 days from date on which fda gives market regulatory approval of product Source - http://1.usa.gov/28Sj3cH (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Palatin Technologies Q3 loss per share $0.08
Tuesday, 17 May 2016 07:35am EDT 

Palatin Technologies Inc : Believes that existing capital resources will be adequate to fund planned operations through quarter ending september 30, 2016 . Palatin technologies, inc. Reports third quarter fiscal year 2016 results; teleconference and webcast to be held on may 17, 2016 .Q3 loss per share $0.08.  Full Article

BRIEF-Palatin Technologies signs agreement with Fosun Pharma

* Palatin Technologies announces signing of licensing agreement with Fosun Pharma rights to bremelanotide in China and other selected territories